Biolexis Therapeutics Scientific Team participates and present their pre-clinical stage small molecule HDAC6 inhibitor program for ALS indication at the “SfN” (Society of Neuroscience) Annual Meeting to be held on Nov 11-15, 2023 – Walter E. Washington Convention Center in Washington, D.C.

https://www.sfn.org/meetings/neuroscience-2023

Abstract Title: Development of a Novel, Orally Active, Brain Penetrable HDAC6 Inhibitors Shows a Therapeutic Potential for Amyotrophic Lateral Sclerosis (ALS)

Session Title: ALS: Non-Human Models

Session Type: Poster | Abstract Control Number: 2773
Session Number: PSTR200 | Presentation Number: PSTR200.26
Session Date and Time: 11/13/2023 8:00:00 AM – 11/13/2023 12:00:00 PM
Location/Room: WCC Halls A-C | Presentation Time: Mon. Nov. 13, 2023, 9:00 AM – 10:00 AM

Biolexis Therapeutics Scientific Team participates and present their IND stage small molecule CDK9 inhibitor program for Pancreatic Cancers indications at The “AACR-NCI-EORTC” International Conference on Molecular Targets and Cancer Therapeutics to be held on Nov 11-15, 2023 – Haynes Convention Center, Boston, Massachusetts

Abstract title: Development of BLX-3030, A Potent, Selective, Orally Available CDK9i shows promise in Pancreatic Ductal Adenocarcinoma (PDAC) Models

Poster number:LB_C13 | Session: Poster Session C     

Session location: Level 2, Exhibit Hall D        

Session date and time: Saturday, October 14 | 12:30 pm-4:00 pm

July 22-24, 2023

Biolexis Therapeutics CSO invited to Chair Cancer Immunology & Immunotherapy session and present MolecuLern technology at 14th Annual World Cancer Congress – WCC 11: Cancer Immunology & Immunotherapy on July 22-24, 2023, at Barcelona, Spain.

WCC-2022 (bitcongress.com)

April 26-27, 2023

Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at Ai-Driven Drug Development Summit Europe on April 26-27, 2023, in London.

AI Driven Drug Development Summit Europe 2023 (aidrugdevelopmentsummiteu.com)

April 14-19, 2023

Biolexis management participates and presents at the AACR (American Association of Cancer Research) Annual Meeting on April 14-19, 2023 – Orange County Convention Center, Orlando, Florida. 

April 8-13, 2023

Biolexis Therapeutics Inc., a leader in bio-tech research and creator of the FIELDS™ process, today announced that data highlighting an orally available, CDK9 selective small molecule inhibitor showing promise in n-Myc-driven neuroendocrine prostate cancers (NEPC) was presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.

https://www.pr.com/press-release/859029

April 10-11, 2023

Biolexis Therapeutics CSO invited to present company MolecuLern™ technology at 2023 Annual San Antonio Drug Discovery Symposium held at Greehey Children’s Cancer Research Institute of University of Texas Health San Antonio.

https://research.utsa.edu/events/2023/04/03-cidd-annual-drug-discovery-symposium.html

April 8-13, 2023

Biolexis management participated and presented pre-clinical data on CDK9 inhibitor at the AACR (American Association of Cancer Research) Annual Meeting on April 8-13, 2022, Ernest N. Morial Convention Center New Orleans, Louisiana.

B137 / 13 – Orally available, CDK9 selective, small molecule inhibitors shows promise in n-Myc-driven neuroendocrine prostate cancers (NEPC)

Session LBPO.MCB02 – Late-Breaking Research: Molecular/Cellular Biology and Genetics 2.

February 22-23, 2023

Biolexis Therapeutics Business Development team participated 2nd Next Generation Kinase Inhibitors Summit was held on February 22-23, 2023, in Boston.

November 14-15, 2022

Biolexis Therapeutics Management participates and presents their MolecuLern technology at Precision in Drug Discovery & Preclinical Summit 2022 on Nov 14-15, 2022, San Francisco CA, US.